fenofibraat

Fenofibrate is a medication belonging to the fibrate class of drugs. It is primarily used to treat dyslipidemia, a condition characterized by abnormal levels of lipids in the blood. Specifically, fenofibrate is effective in lowering elevated triglycerides and increasing high-density lipoprotein (HDL) cholesterol, often referred to as "good" cholesterol. It can also modestly lower low-density lipoprotein (LDL) cholesterol, or "bad" cholesterol.

The mechanism of action of fenofibrate involves the activation of peroxisome proliferator-activated receptor alpha (PPARα). This activation leads to changes in gene expression that influence lipid metabolism. It promotes the breakdown of triglycerides and the clearance of very-low-density lipoproteins (VLDL) from the bloodstream. Simultaneously, it enhances the production of HDL particles.

Fenofibrate is typically prescribed to individuals with hypertriglyceridemia and mixed dyslipidemia, particularly those who have not achieved adequate lipid control with lifestyle modifications alone. It is often used in conjunction with statins in certain high-risk patient populations, although co-administration requires careful consideration due to potential side effects.

Common side effects of fenofibrate may include gastrointestinal disturbances such as nausea, abdominal pain, and diarrhea. Liver function abnormalities can occur, necessitating regular monitoring. Muscle-related side effects, though less common than with statins, are also a possibility. Fenofibrate is contraindicated in patients with severe kidney or liver disease, gallbladder disease, and known hypersensitivity to the drug.